First-Line Immune Tx: An Option in V600K-Mutant Melanoma (CME/CE)

(MedPage Today) -- Higher mutational load in BRAF-mutant V600K genotype translates into better response to anti-PD1 immunotherapy than targeting BRAF/MEK
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news